We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Merck Serono Appoints Luciano Rossetti
News

Merck Serono Appoints Luciano Rossetti

Merck Serono Appoints Luciano Rossetti
News

Merck Serono Appoints Luciano Rossetti

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Merck Serono Appoints Luciano Rossetti"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Merck Serono has announced the appointment of Luciano Rossetti, M.D., as Executive Vice President and Global Head of Research & Development as of July 21, 2014.

In his most recent role Rossetti (57) acted as Senior Vice President Late Stage Development at Merck Sharp & Dohme, or MSD. In this position, he was responsible for the entire clinical development from Phase II to Phase V across all therapeutic areas.

At MSD, he played a key role in shaping and implementing the development strategy of several potential compounds such as Anti PD-1. He also restructured the clinical genetics group to better leverage the collaboration between discovery and clinical development. Before joining MSD in 2006, Rossetti was an internationally recognized academic scientist for 18 years.

“I’m thrilled to welcome Luciano Rossetti to Merck,” said Belén Garijo, President and CEO at Merck Serono. “His breadth of experience and solid track record in both research as well as development together with his distinct leadership profile will be instrumental in driving the development of our promising pipeline to ensure that we will meet our strategic milestones and deliver innovative solutions for unmet medical needs to patients around the world.”

Rossetti will be based in Billerica, outside Boston, Massachusetts (U.S.), and share his time between Merck’s headquarters in Darmstadt (Germany) and Billerica - one of Merck Serono’s four global R&D hubs.

Advertisement